Premium
O2–05–05: Comparison of soluble apoptosis mediators in Alzheimer patients with depression and Alzheimer patients without symptoms of depression
Author(s) -
Politis Antonis,
Piperi C.,
Stamouli E.,
Maillis A.,
Kalofoutis A.,
Soldatos C.R.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.142
Subject(s) - proinflammatory cytokine , depression (economics) , medicine , outpatient clinic , tumor necrosis factor alpha , dementia , cytokine , population , disease , oncology , immunology , endocrinology , inflammation , environmental health , economics , macroeconomics
adjuvant only (n 13), starting at 2 months. Tau-specific immunoglobulin titers were determined and at 5 months their brains were processed for tau biochemistry and histology. A separate group of vaccinated mice (n 12) and controls (n 12) received injections from 2 months and were tested on various sensorimotor tasks (rotarod, traverse beam, locomotor activity) at 5 months. These animals will be retested periodically and their brains subsequently analyzed. Results: The vaccine elicited a robust tau-specific antibody response, associated with a reduction in aggregated tau (47%; p 0.04) in the brain but soluble tau levels were unaltered, compared to the control group. The immunized animals performed better than the controls on the rotarod (p 0.02) and the traverse beam (p 0.001), and attained greater speed (Vmax) in the locomotor task (p 0.01). Histological evaluation is underway. Conclusion: Active immunization with a phospho-tau derivative peptide reduces brain levels of aggregated tau and slows the progression of tangle-related behavioral phenotype.